BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36890092)

  • 21. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
    Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
    Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.
    Khaznadar Z; Boissel N; Agaugué S; Henry G; Cheok M; Vignon M; Geromin D; Cayuela JM; Castaigne S; Pautas C; Raffoux E; Lachuer J; Sigaux F; Preudhomme C; Dombret H; Dulphy N; Toubert A
    J Immunol; 2015 Sep; 195(6):2580-90. PubMed ID: 26246143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
    Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpressed mitogen-and stress-activated protein kinase 1 promotes the resistance of cytarabine in acute myeloid leukemia through brahma related gene 1-mediated upregulation of heme oxygenase-1.
    Zhang S; Pan C; Shang Q; Wang W; Hu T; Liu P; Chen S; Wang J; Fang Q
    Eur J Pharmacol; 2022 Feb; 917():174722. PubMed ID: 34953799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HO-1 downregulation favors BRAF
    Furfaro AL; Ottonello S; Loi G; Cossu I; Piras S; Spagnolo F; Queirolo P; Marinari UM; Moretta L; Pronzato MA; Mingari MC; Pietra G; Nitti M
    Int J Cancer; 2020 Apr; 146(7):1950-1962. PubMed ID: 31376303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
    Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
    J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
    Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
    J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
    Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
    Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
    Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
    Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction.
    Rushworth SA; Bowles KM; Raninga P; MacEwan DJ
    Cancer Res; 2010 Apr; 70(7):2973-83. PubMed ID: 20332229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
    Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
    Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
    Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.
    Bou-Tayeh B; Laletin V; Salem N; Just-Landi S; Fares J; Leblanc R; Balzano M; Kerdiles YM; Bidaut G; Hérault O; Olive D; Aurrand-Lions M; Walzer T; Nunès JA; Fauriat C
    Front Immunol; 2021; 12():730970. PubMed ID: 34975835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells.
    Dulphy N; Chrétien AS; Khaznadar Z; Fauriat C; Nanbakhsh A; Caignard A; Chouaib S; Olive D; Toubert A
    Front Immunol; 2016; 7():94. PubMed ID: 27014273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1.
    Heasman SA; Zaitseva L; Bowles KM; Rushworth SA; Macewan DJ
    Oncotarget; 2011 Sep; 2(9):658-68. PubMed ID: 21911919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.
    Wang Y; Chen C; Dong F; Ma S; Xu J; Gong Y; Cheng H; Zhou Y; Cheng T; Hao S
    Sci China Life Sci; 2015 Dec; 58(12):1288-98. PubMed ID: 26588911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
    Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.
    Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
    Haematologica; 2014 May; 99(5):836-47. PubMed ID: 24488563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
    Ingram W; Chan L; Guven H; Darling D; Kordasti S; Hardwick N; Barber L; Mufti GJ; Farzaneh F
    Br J Haematol; 2009 Jun; 145(6):749-60. PubMed ID: 19388935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.